Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663604 | 0.91 | HDAC2 (0.55) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3659009 | 0.89 | HDAC2 (0.71) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3660157 | 0.88 | HDAC2 (0.54) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3660722 | 0.88 | HDAC2 (0.55) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3663432 | 0.87 | HDAC1 (0.60) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3664762 | 0.87 | HDAC1 (0.60) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3665620 | 0.87 | HDAC2 (0.58) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3661503 | 0.86 | HDAC1 (0.61) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3665701 | 0.86 | HDAC1 (0.63) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 | |
| SCHEMBL3660130 | 0.86 | HDAC2 (0.70) | HDAC2HDAC1HPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC2 4/4885HDAC1 1/4885HPGD 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.